Biomarkers /

CDH23

Back to Biomarkers List

Overview

Location [1]
10q22.1
Protein [2]
Cadherin-23
Synonyms [1]
PITA5, CDHR23, USH1D

CDH23 is altered in 0.47% of all cancers with prostate adenocarcinoma, high grade ovarian serous adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and endometrial serous adenocarcinoma having the greatest prevalence of alterations [3].

CDH23 GENIE Cases - Top Diseases

The most common alterations in CDH23 are CDH23 V751I (0.56%), CDH23 R3229W (0.39%), CDH23 I1572T (0.35%), CDH23 P1489L (0.35%), and CDH23 R2511Q (0.44%) [3].

CDH23 GENIE Cases - Top Alterations

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.